healthevidencedigest

Tag: FDA approvals

  • The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice.

    The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice.

    📌 The essentials Foundayo (orforglipron) was approved by the FDA on April 1, 2026 as the first non-peptide, small molecule oral GLP-1 receptor agonist for chronic weight management. It was approved 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. As part of the FDA approval letter, Eli Lilly is required to conduct several post-marketing studies. Per the FDA approval letter, these include: evaluation of major adverse cardiovascular events (MACEs) and drug-induced liver injury (DILI); assessment of delayed gastric emptying and aspiration risk; a lactation study to measure drug concentrations in breast milk; pediatric trials in patients aged 6 to 12; and pregnancy registry data. The FDA is also requiring enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases. Lilly has also separately released ACHIEVE-4 trial data showing non-inferior MACE risk compared to insulin glargine, which directly addresses the cardiovascular monitoring requirement. What this does not mean: post-marketing study requirements are routine for obesity medications and do not reflect a finding that the drug is unsafe. Foundayo was approved based on the ATTAIN clinical program data. The post-marketing studies reflect normal FDA practice of continuing safety surveillance after approval, particularly for a new molecular class with limited long-term data.

    Foundayo (orforglipron) was the most talked-about obesity drug approval of 2026. Not just because of what it is, the first oral GLP-1 receptor agonist that does not require a peptide injection and has no food or water restrictions, but because of how fast it happened. The FDA approved it 50 days after Eli Lilly submitted the NDA, making it the fastest approval of a new molecular entity since 2002, and the first new molecular entity approved under the Commissioner’s National Priority Voucher program.

    What received less coverage in that story is a standard part of every major drug approval: the FDA’s post-marketing study requirements. These are the conditions attached to the approval letter specifying additional clinical studies Lilly must conduct now that the drug is on the market. A Reuters report noted some of these requirements shortly after the approval. This post looks directly at the FDA approval letter, explains what each requirement is and why it exists, and puts the requirements in context for the broader GLP-1 obesity treatment landscape.

    For a full overview of what Foundayo is, how orforglipron works, and what the ATTAIN clinical trial data showed, see our main post: Foundayo: The First Once-Daily GLP-1 Pill for Weight Loss.

    What Orforglipron Is and Why It Is Different

    Orforglipron is a small molecule, non-peptide GLP-1 receptor agonist. Every GLP-1 receptor agonist currently approved in the United States before Foundayo, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), is based on a peptide molecule, a chain of amino acids structurally similar to the natural GLP-1 hormone. Because peptides are broken down in the stomach, most of these drugs are injectable. The one exception, Rybelsus (oral semaglutide), requires fasting for 30 minutes and a small amount of water to achieve adequate absorption.

    Orforglipron is fundamentally different. It is a small organic molecule, not a peptide, that binds to and activates the same GLP-1 receptor. Its small molecule structure allows it to survive oral digestion without the absorption restrictions that peptide-based oral semaglutide requires. It can be taken at any time of day, with or without food, and without water restrictions.

    This is a genuine pharmacological advance. The practicality difference between taking a once-weekly injection, taking a pill at a specific time under fasting conditions, and taking a pill whenever you want matters for real-world adherence, particularly among the more than 90% of eligible patients who are not currently on any GLP-1 therapy.

    The ATTAIN clinical program demonstrated that in the ATTAIN-1 trial, patients taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4% of body weight) compared to 2.2 pounds (0.9%) with placebo. Across all trial completers regardless of dose escalation, average weight loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo. The drug also showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

    What Post-Marketing Studies Are and Why They Are Routine

    Before getting into the specific requirements for Foundayo, it is worth explaining what post-marketing study requirements actually are, because the framing of “FDA requires studies” can sound more alarming than it is.

    Every major drug approval, particularly for new molecular entities in new drug classes, comes with post-marketing commitments and requirements. These fall into two categories:

    Post-marketing commitments (PMCs): voluntary agreements where the sponsor agrees to conduct additional studies, often to explore dosing, new populations, or drug interactions.

    Post-marketing requirements (PMRs): studies the FDA requires by law because specific safety questions cannot be adequately answered through nonclinical data or observational surveillance alone. They are written into the approval letter.

    The distinction matters: PMRs do not mean the drug has a safety problem. They mean the FDA identified specific questions about safety in populations or settings that were not fully characterized in the pivotal trial program, and that randomized, controlled prospective data is needed to answer those questions properly. This is how responsible post-market surveillance of new drug classes works.

    GLP-1 receptor agonists as a class have been subject to ongoing FDA safety monitoring since the class was first approved, including reviews of suicidal ideation reports (for which the FDA ultimately concluded in 2024 that the available evidence does not support a causal relationship between GLP-1 receptor agonists and suicidal behavior), thyroid cancer signals, and pancreatitis risk. Foundayo’s post-marketing requirements build on this established framework.

    The Specific Post-Marketing Requirements for Foundayo

    Based on the FDA approval letter and coverage of the approval letter contents, the following post-marketing study requirements are in place for Foundayo:

    1. Cardiovascular outcomes (MACEs)

    What is required: A prospective randomized trial evaluating major adverse cardiovascular events (MACEs), specifically heart attack, stroke, cardiovascular death, and unstable angina requiring hospitalization.

    Why this is required: The FDA requires all new diabetes and obesity drugs to demonstrate cardiovascular safety through adequate CVOT (cardiovascular outcomes trial) data. The pivotal ATTAIN trials were designed to demonstrate weight loss efficacy and were not powered or designed as cardiovascular outcomes studies. The FDA therefore requires a dedicated CVOT to characterize the full cardiovascular risk-benefit profile of orforglipron in a larger population over longer follow-up.

    Current status: Lilly has already released results from the Phase 3 ACHIEVE-4 trial (NCT05803421), which evaluated orforglipron versus insulin glargine in patients with type 2 diabetes. ACHIEVE-4 showed non-inferior risk for MACEs compared to insulin glargine and detected no safety signal for drug-induced liver injury. Lilly has indicated it plans to submit an NDA for Foundayo in type 2 diabetes by the end of Q2 2026, supported by this data. The ACHIEVE-4 results partially address the cardiovascular monitoring requirement, though the FDA will specify the scope of ongoing data requirements.

    2. Drug-induced liver injury (DILI)

    What is required: Enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases and periodic cumulative safety analyses.

    Why this is required: New small molecule drugs, particularly those in new molecular classes, are monitored carefully for hepatotoxicity signals that may not have been apparent in pivotal trials. The ACHIEVE-4 trial found no safety signal for liver injury, but the FDA is requiring systematic prospective surveillance across the broader post-market population.

    Context: Drug-induced liver injury is one of the most common reasons for post-market drug withdrawals and is a priority safety monitoring target for the FDA across drug classes. The 5-year enhanced surveillance period is a standard precautionary measure for new molecular entities.

    3. Delayed gastric emptying and aspiration risk

    What is required: Assessment of the drug’s effects on gastric emptying rate and associated aspiration risk, particularly relevant in the context of anesthesia and sedation procedures.

    Why this is required: GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, and this effect has clinical implications for patients undergoing procedures requiring anesthesia or sedation. The American Society of Anesthesiologists has issued guidance on GLP-1 agonists in the perioperative setting, recommending holding these medications before procedures. The FDA’s requirement for orforglipron specifically is to characterize the gastric emptying effect of the oral formulation, which may have different pharmacokinetics than injectable versions.

    4. Lactation study

    What is required: A study measuring drug concentrations in breast milk in nursing mothers.

    Why this is required: The pivotal trials excluded pregnant and breastfeeding women. The FDA requires a lactation study to determine the extent to which orforglipron is transferred into breast milk, as this directly informs prescribing decisions for women who are breastfeeding and clinicians counseling them on the drug’s safety in this setting.

    5. Pediatric trials (ages 6 to 12)

    What is required: Clinical trials in pediatric patients aged 6 to 12 years with obesity.

    Why this is required: The Pediatric Research Equity Act (PREA) generally requires sponsors to study new drugs in pediatric populations unless a waiver is granted. The FDA waived the under-6 age group, citing limited expected use and therapeutic benefit in very young children. The 6 to 12 age group is included given that childhood and adolescent obesity is a significant clinical problem and clinicians will eventually prescribe this drug in younger patients.

    6. Pregnancy registry

    What is required: A structured pregnancy exposure registry to capture outcomes in women who become pregnant while taking Foundayo.

    Why this is required: GLP-1 medications should be discontinued before attempting conception because of potential fetal effects, but unintended pregnancies during treatment are well documented across this drug class. The pregnancy registry will systematically capture data on fetal outcomes in women with inadvertent first-trimester exposure, building a real-world safety database that cannot be generated from controlled trials.

    Hair loss: a side effect, not a post-marketing study requirement The stub post on this topic framed hair loss as equivalent to the post-marketing study requirements above. This needs clarification. Hair loss is listed as a common side effect in the Foundayo prescribing information, alongside nausea, constipation, diarrhea, and other GI effects. It was observed in the ATTAIN trials and is included in the approved label. It is not a specific named post-marketing study requirement in the same category as the CVOT or DILI monitoring. Hair loss has been observed with GLP-1 medications more broadly and is believed to be related to the physiological stress of rapid weight loss (telogen effluvium) rather than a direct drug effect. Patients who experience hair loss on Foundayo should discuss it with their prescriber; it is typically reversible as weight stabilizes.

    Why This Pattern Is Consistent With the CNPV Approval Context

    The speed of Foundayo’s approval under the CNPV program, 50 days from NDA submission, is directly relevant to understanding why the post-marketing study package is robust. The CNPV program compresses FDA review timelines dramatically but does not reduce the evidentiary standard for approval. For a novel molecular entity in a new drug class, some safety questions that would normally be answered in a longer review process are instead addressed through post-market commitments.

    This is not unique to Foundayo. Wegovy HD (semaglutide 7.2 mg), which was also approved under the CNPV program, similarly came with post-marketing monitoring requirements. The CNPV program approval speed and the post-marketing study requirements are two parts of the same regulatory approach: approve based on strong efficacy and acceptable safety from the clinical program, then require prospective data to fill the remaining gaps systematically.

    The FDA’s approach to Foundayo reflects a broader evolution in how it handles obesity drug safety. After the experience with earlier obesity drugs including sibutramine (withdrawn for cardiovascular risk) and fenfluramine (withdrawn for valvular heart disease), the FDA has taken a systematically cautious approach to post-market safety surveillance for this class, requiring dedicated CVOT data and structured monitoring programs.

    What Patients Taking Foundayo Should Know

    If you are taking or considering Foundayo for weight management, the post-marketing study requirements do not indicate that the drug is unsafe. They indicate that the FDA is conducting the normal, responsible surveillance that accompanies every major new drug class approval.

    The safety profile documented in the ATTAIN trials showed that the most common side effects were gastrointestinal, including nausea, constipation, diarrhea, vomiting, and abdominal pain. These are consistent with the established profile of the GLP-1 receptor agonist class. Hair loss was also reported and is typically temporary.

    Key practical points:

    • Foundayo should be discontinued at least 2 months before planned conception, consistent with guidance across the GLP-1 class. Effective contraception during treatment is recommended.
    • Inform your anesthesia provider that you are taking Foundayo before any scheduled procedure requiring general anesthesia or deep sedation, as the gastric emptying effect is clinically relevant in this setting.
    • Report any symptoms of liver injury, including unusual fatigue, jaundice, or upper right abdominal pain, to your prescriber promptly.
    • Do not use Foundayo with other GLP-1 receptor agonists.

    For more on how GLP-1 medications interact with reproductive health considerations, see our post on GLP-1 medications, PCOS, and the fertility and pregnancy evidence in 2026.

    Sources

    FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.

    FDA approval letter: Foundayo (orforglipron) NDA approval letter. accessdata.fda.gov. April 1, 2026.

    Lilly approval press release: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.

    Clinical Trials Arena post-marketing coverage: Lilly debuts more Foundayo data as FDA requests post-marketing trials. clinicaltrialsarena.com. April 16, 2026.

    Pharmacally post-marketing requirements detail: FDA Requires Extensive Postmarketing Safety Data for Foundayo. pharmacally.com. April 2026.

    Foundayo drug history: Foundayo (orforglipron) FDA Approval History. drugs.com.

    ACHIEVE-4 trial registration: NCT05803421. ClinicalTrials.gov.

    FDA GLP-1 and suicidal ideation review: Information About Suicidal Thoughts, Behavior, and GLP-1 Receptor Agonists. FDA.gov.

    Post-marketing studies FDA guidance: Postmarketing Studies and Clinical Trials: Guidance for Industry. FDA.gov.

    GLP-1 gastric emptying clinical review: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.

    PREA pediatric requirement: Pediatric Research Equity Act. FDA.gov.

    DILI overview: Drug-Induced Liver Injury. StatPearls. NCBI.

    ASA GLP-1 perioperative guidance: American Society of Anesthesiologists Guidance on GLP-1 Receptor Agonists. asahq.org.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about obesity treatment, including whether Foundayo is appropriate for your situation, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals.
  • That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For

    That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For

    📌 The essentials On April 22, 2026, the FDA approved Lynavoy (linerixibat, GSK), an oral ileal bile acid transporter (IBAT) inhibitor, for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This is the first FDA-approved therapy specifically indicated for cholestatic pruritus in PBC. It is a full approval, not accelerated, meaning the FDA reviewed actual clinical benefit data. The clinical basis: the Phase 3 GLISTEN trial (NCT03706547) enrolling 238 patients with moderate to severe cholestatic pruritus, showing statistically significant reduction in worst itch NRS score versus placebo (p less than 0.001), with rapid onset by week 2 and benefit sustained through 24 weeks. Sleep quality also improved significantly (p=0.024). Key safety consideration: diarrhea occurred in 61% of patients in GLISTEN, the majority mild to moderate. Discontinuation rate due to diarrhea was approximately 4%. What it does not do: Lynavoy is not a disease-modifying therapy for PBC. It does not slow liver disease progression or replace existing PBC treatments including UDCA or obeticholic acid. It treats the itch.

    There is a particular kind of suffering that does not show up well on a lab report. Cholestatic pruritus, the relentless, internal itch caused by bile acid accumulation in primary biliary cholangitis, is one of them. It does not scratch away. It does not respond to antihistamines. It keeps patients awake at 3 a.m., disrupts concentration, and compounds the psychological weight of already managing a progressive autoimmune liver disease.

    On April 22, 2026, the FDA approved Lynavoy (linerixibat), GSK’s oral IBAT inhibitor, specifically for cholestatic pruritus in adults with PBC. It is the first medicine approved in the United States for this indication. As approvals go, this is one where the clinical evidence and the patient need are unusually well-aligned.

    What Is Primary Biliary Cholangitis?

    PBC is a rare, chronic autoimmune liver disease in which the immune system mistakenly attacks the small bile ducts inside the liver. As those ducts are damaged and scarred over time, bile cannot drain properly; it backs up into the liver and eventually into the bloodstream.

    The disease affects roughly 1 in 1,000 women over 40, though it is underdiagnosed and can affect men as well. Without effective management, PBC can progress to cirrhosis, liver failure, and the need for transplantation.

    Cholestatic pruritus affects up to 89% of people with PBC at some point during the disease. It is caused by the accumulation of bile acids in the skin and blood, and it is notoriously difficult to treat. Before Lynavoy, available options were largely off-label, inconsistently effective, and sometimes poorly tolerated. For many patients, managing the itch meant cycling through treatments that did not really work.

    How Linerixibat Works

    Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. Under normal circumstances, the IBAT protein in the small intestine reabsorbs bile acids from the gut back into circulation, a recycling loop that keeps the body’s bile acid pool stocked. In PBC, where the liver is already struggling to process that pool, this recycling makes the problem worse.

    Linerixibat blocks the IBAT pump in the gut, preventing that reabsorption. Fewer bile acids recirculate. Levels in the blood and skin drop. And for many patients, so does the itch.

    It is a targeted, mechanistically rational approach. Because it acts locally in the gut rather than systemically, it avoids some of the side effects associated with older therapies like cholestyramine.

    Why does blocking gut bile acid recycling help with itch in the skin? Bile acids that recirculate from the gut end up in systemic blood, and from there accumulate in peripheral tissues including the skin. The exact mechanism by which bile acids trigger itch is not fully established; it likely involves bile acid receptors on sensory nerve fibers, specifically the TGR5 receptor and the bile acid-sensitive ion channel TRPA1. The clinical correlation between bile acid levels and itch severity is well-documented. Reducing the circulating load through IBAT inhibition targets the source of the symptom rather than suppressing the itch signal downstream.

    The GLISTEN Trial: What the Data Shows

    The pivotal GLISTEN Phase 3 trial (NCT03706547) enrolled 238 patients with PBC and moderate to severe cholestatic pruritus. Participants were randomized to linerixibat or placebo for 24 weeks. The primary endpoint was itch intensity, measured using the Numerical Rating Scale (NRS) for worst itch, a validated patient-reported outcome that captures what patients actually experience rather than a laboratory surrogate.

    EndpointResultStatistical significance
    Worst itch NRS reduction vs. placeboStatistically significant mean differencep less than 0.001
    Sleep quality improvement (NRS)Significant improvement vs. placebop=0.024
    Onset of itch benefitDetectable by week 2—
    Duration of benefitSustained through 24 weeks—
    Diarrhea (all grade)61% in linerixibat armDiscontinuation rate ~4%
    Abdominal pain18% in linerixibat armDiscontinuation rate less than 1%

    Source: GLISTEN Phase 3 trial, NCT03706547. GSK press release, April 22, 2026.

    The sleep quality finding deserves equal weight as the itch reduction data. In qualitative research and patient surveys, pruritus-related sleep disruption consistently ranks as one of the most burdensome aspects of PBC, sometimes more so than concerns about disease progression. A therapy that demonstrably improves both itch intensity and sleep quality is addressing the full clinical picture of what patients report as most disruptive to their daily lives.

    The diarrhea rate of 61% is notable and warrants clear communication with patients before initiating therapy. Most cases were mild to moderate, and the discontinuation rate of approximately 4% was low, but this is a side effect that will affect real-world tolerability, particularly for patients who are already managing fatigue and GI sensitivity as part of their PBC picture. Clinicians prescribing Lynavoy will need to set expectations carefully and discuss management strategies, including dose timing, dietary considerations, and when dose adjustment is appropriate.

    The full approval status matters here. This is not accelerated approval based on a surrogate biomarker. The FDA reviewed patient-reported outcome data on actual symptom reduction and determined it met the standard for substantial evidence of clinical benefit. That is a meaningful regulatory bar, and the GLISTEN data cleared it.

    Dr. Christopher Bowlus, Chief of Gastroenterology and Hepatology at UC Davis Health and a principal investigator in the linerixibat program, characterized the approval as representing an important opportunity to improve the lives of people with PBC who struggle with uncontrolled and often debilitating pruritus. That framing reflects the clinical reality: “uncontrolled and often debilitating” is not hyperbole in this patient population.

    What This Approval Does Not Answer

    Does treating the itch affect disease progression?

    Lynavoy is approved specifically for symptom management, not as a disease-modifying therapy for PBC itself. Patients with PBC who need a medication to slow liver disease progression are managed with ursodeoxycholic acid (UDCA) or obeticholic acid. Linerixibat does not replace those. Whether there is any long-term hepatoprotective effect from reducing bile acid recirculation has not been established and should not be assumed from the GLISTEN data, which was not designed or powered to assess disease progression.

    Real-world tolerability

    Trial populations tend to be healthier and more closely monitored than the broader patient population. The 61% diarrhea rate in GLISTEN will bear watching in post-market use, particularly in older patients or those with baseline GI sensitivity who were not well represented in the trial. Patient registries and observational data over the next one to two years will be more informative here than the trial data alone.

    Cost and access

    Lynavoy carries Orphan Drug Designation, which typically supports premium pricing and seven years of market exclusivity. GSK has not yet announced U.S. list pricing. For a symptom-focused therapy in a rare disease, the cost-benefit calculus for payers is different than for a life-prolonging treatment, which could create coverage access hurdles worth monitoring. GSK’s patient support program details will matter significantly for patients navigating these conversations.

    The Broader Context: IBAT Inhibitors and Cholestatic Liver Disease

    Linerixibat’s approval in adult PBC is part of a broader story in hepatology. The IBAT inhibitor mechanism has already demonstrated clinical utility in pediatric cholestatic conditions. Maralixibat (Livmarli) is approved for cholestatic pruritus in Alagille syndrome, and odevixibat (Bylvay) is approved for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC). The validation of this mechanism in adult PBC extends the evidence base for IBAT inhibition across cholestatic conditions and may support future investigation in other forms of cholestatic liver disease where pruritus remains inadequately managed.

    Lynavoy is also GSK’s first FDA-approved liver medicine from its hepatology pipeline, reflecting a deliberate strategic move for a company historically stronger in respiratory and immunology. A partnership with Alfasigma S.p.A. covers global commercialization, with regulatory submissions underway in the EU, UK, Canada, and China. Whether this represents a durable GSK hepatology platform or a single-indication program will become clearer as the pipeline matures.

    For context on how the FDA approaches safety monitoring for rare disease liver conditions, see our coverage of the Tavneos (avacopan) serious liver injury warning and the ongoing regulatory dispute between the FDA and Amgen over voluntary withdrawal.

    For Patients and Caregivers

    For adults living with PBC and cholestatic pruritus who have not achieved adequate itch relief with currently available treatments, Lynavoy adds the first indication-specific approved option in the United States. The conversation about whether it is appropriate for an individual patient belongs with a gastroenterologist or hepatologist who is familiar with the full picture of disease activity, current medications, and GI tolerance.

    The PBCers Organization is the primary U.S. patient advocacy group for primary biliary cholangitis and has responded to the Lynavoy approval as a significant step forward for those dealing with chronic, uncontrolled itch. Their resources, community forums, and physician directory are the best starting point for patients navigating this diagnosis. The American Liver Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases also maintain current clinical information on PBC management.

    The GLISTEN trial is complete. Ongoing clinical trials for PBC and cholestatic liver disease can be searched at ClinicalTrials.gov for patients interested in research participation.

    Sources

    GSK FDA approval press release: GSK Announces U.S. FDA Approval of Lynavoy (linerixibat), the First and Only Medicine Approved in the US Specifically for Cholestatic Pruritus in Adults with Primary Biliary Cholangitis (PBC). April 22, 2026. gsk.com.

    GLISTEN trial registration: NCT03706547. A Phase III Study to Evaluate the Efficacy and Safety of Linerixibat in Participants with Primary Biliary Cholangitis with Cholestatic Pruritus. ClinicalTrials.gov.

    PBC epidemiology and pruritus burden: Primary Biliary Cholangitis: Epidemiology and Quality of Life. PMC7510845.

    Cholestatic pruritus overview: Cholestatic Pruritus. StatPearls. NCBI.

    IBAT inhibitor mechanism: Ileal Bile Acid Transporter Inhibitors as a Novel Therapeutic Approach. PMC7387516.

    UDCA in PBC: Ursodeoxycholic Acid. StatPearls. NCBI.

    Obeticholic acid FDA approval: FDA approves obeticholic acid for primary biliary cholangitis. FDA.gov.

    Maralixibat FDA approval: FDA approves maralixibat chloride for Alagille syndrome. FDA.gov.

    Odevixibat FDA approval: FDA approves odevixibat for pruritus in cholestatic liver disease. FDA.gov.

    PBC NIDDK overview: Primary Biliary Cholangitis. NIDDK.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    Patient resources: PBCers Organization | American Liver Foundation: PBC | NIDDK PBC | ClinicalTrials.gov: PBC pruritus

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about PBC treatment, including whether linerixibat is appropriate for your situation, should be made in consultation with a qualified gastroenterologist or hepatologist familiar with your individual disease status, treatment history, and current medications.

  • AVLAYAH Approved: For Hunter Syndrome Families, This FDA Decision Hits Different

    AVLAYAH Approved: For Hunter Syndrome Families, This FDA Decision Hits Different

    📌 The essentials On March 25, 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm, Denali Therapeutics) for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, MPS II) in pediatric patients weighing at least 5 kg, when initiated prior to advanced neurologic impairment. This is the first FDA-approved therapy specifically designed to cross the blood-brain barrier, and the first new FDA-approved treatment for Hunter syndrome in nearly 20 years. The clinical basis: Phase 1/2 trial (NCT02055118) in 47 patients (ages 0.3 to 13 years, median age 5), showing 91% reduction in CSF heparan sulfate (95% CI: 89% to 92%) by week 24, with 93% of treated patients (41 of 44) reaching CSF HS levels within the range of unaffected individuals. Secondary endpoints included improvements in Vineland-3 adaptive behavior scores, Bayley Scales of Infant and Toddler Development (BSID-III), liver volume normalization, and hearing. Accelerated approval context: continued approval may be contingent on the ongoing Phase 2/3 COMPASS confirmatory trial, which randomizes patients 2:1 to AVLAYAH versus idursulfase (standard of care) over 96 weeks. A Rare Pediatric Disease Priority Review Voucher was granted alongside the approval.

    When the National MPS Society shared news of the AVLAYAH approval on social media, the comments section filled with responses from parents who had been tracking this program for years. “We’ve been waiting 18 years for this.” That context is worth keeping in mind as we go through what this approval actually means, and what it does not yet answer.

    AVLAYAH (tividenofusp alfa-eknm), developed by Denali Therapeutics, received FDA accelerated approval on March 25, 2026, as a treatment for Hunter syndrome (MPS II). It is the first new therapy for this condition in nearly two decades. It is also the first therapy ever designed to reach the brain.

    What Is Hunter Syndrome?

    Hunter syndrome (MPS II) is a rare, X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate 2-sulfatase (IDS). Without sufficient IDS, complex sugars called glycosaminoglycans (GAGs), specifically heparan sulfate and dermatan sulfate, accumulate in cells throughout the body.

    The condition is estimated to affect fewer than 500 people in the United States, almost all of them male. The consequences compound over time: developmental delays, cognitive regression, hearing loss, progressive joint stiffness, and organ dysfunction. The disease has a neuronopathic form, where the accumulation affects the brain and causes progressive neurological deterioration, and a non-neuronopathic form with primarily somatic (body) manifestations.

    The existing treatment, Elaprase (idursulfase, Takeda), was approved in 2006. It has been the only FDA-approved therapy for Hunter syndrome for nearly 20 years. It reduces GAG accumulation in peripheral tissues and improves some physical symptoms, but it does not meaningfully cross the blood-brain barrier. Families managing the neuronopathic form have watched their children lose cognitive and developmental ground knowing that existing enzyme replacement therapy simply could not reach where the damage was happening.

    What AVLAYAH Does Differently: The Blood-Brain Barrier Problem

    The blood-brain barrier (BBB) is a highly selective physical barrier formed by the specialized endothelial cells lining brain capillaries. It protects the central nervous system from pathogens and toxins but also blocks the passage of most large molecules, including therapeutic proteins. Most enzyme replacement therapies, regardless of how effective they are in peripheral tissues, cannot reach the brain in therapeutic concentrations.

    Denali’s approach to this problem is their TransportVehicle (TV) platform, which engineers therapeutic molecules to exploit a transport system the brain’s own blood vessels already use. The transferrin receptor (TfR1) is expressed on brain endothelial cells and mediates the transport of iron-bound transferrin across the BBB through receptor-mediated transcytosis. By engineering a therapeutic molecule to bind TfR1 with carefully tuned affinity, Denali can hitch the molecule across the BBB using this existing transport pathway.

    Tividenofusp alfa consists of the IDS enzyme fused to an antibody fragment targeting TfR1. After intravenous infusion, the molecule circulates through the bloodstream, reaches brain blood vessels, binds to TfR1 on those vessels, and is transported into the brain, where the enzyme can then begin reducing the heparan sulfate accumulation that drives neurological deterioration. The same molecule also distributes to peripheral tissues, addressing the somatic manifestations of the disease through a standard intravenous infusion route, without requiring intrathecal (spinal) administration.

    No spinal tap required. That is not a minor practical detail for pediatric patients and their families.

    The Phase 1/2 Trial: What the Data Shows

    The FDA accelerated approval is based on data from a Phase 1/2 international, multicenter, open-label trial (NCT02055118) published in the New England Journal of Medicine on January 1, 2026. The trial enrolled 47 patients with Hunter syndrome, including both enzyme replacement therapy-naive patients (n=15) and previously treated patients (n=32). Ages ranged from 0.3 to 13 years, with a median age of 5.

    The primary objective was safety and tolerability. Secondary objectives evaluated CNS and peripheral effects through multiple biomarker and clinical measures.

    EndpointResultDetail
    CSF heparan sulfate reduction at week 2491% reduction from baseline95% CI: 89% to 92%
    Patients reaching normal CSF HS range at week 2493% (41 of 44 evaluable)Levels within range of individuals without Hunter syndrome
    Vineland-3 adaptive behaviorImprovements observedMeasures real-world functional skills: communication, daily living, socialization
    BSID-III developmental scalesImprovements observedBayley Scales of Infant and Toddler Development
    Liver volumeNormalization observedHepatomegaly is a characteristic feature of MPS II
    HearingImprovements observedHearing loss is a common complication of MPS II
    Most common adverse reactionInfusion-related reactionsConsistent with other enzyme replacement therapies

    Source: Denali Therapeutics FDA approval press release, March 25, 2026. New England Journal of Medicine. January 1, 2026. Phase 1/2 tividenofusp alfa in MPS II.

    The 91% reduction in CSF heparan sulfate with 93% of patients reaching the normal range is a striking biomarker result for a rare disease study of this size. The secondary signals in adaptive behavior, developmental assessments, liver volume, and hearing add clinical texture to the biomarker data, suggesting the molecular effect is translating into meaningful functional signals across multiple organ systems.

    Dr. Joseph Muenzer, MD, PhD, Director of the Muenzer MPS Research and Treatment Center and the Bryson Distinguished Professor in Pediatric Genetics at the University of North Carolina at Chapel Hill, described the approval as a breakthrough advance and the first therapeutic innovation for the Hunter syndrome community in nearly 20 years in a statement accompanying the approval announcement.

    What accelerated approval means here, and why the distinction matters Accelerated approval means the FDA accepted CSF heparan sulfate reduction as a surrogate endpoint reasonably likely to predict clinical benefit, a common pathway for rare diseases where full outcome trials would take years and withholding a promising therapy during that time carries its own cost. AVLAYAH still needs to demonstrate in the ongoing Phase 2/3 COMPASS study that reducing heparan sulfate actually slows or prevents cognitive decline at the clinical level. That is a meaningful distinction for families making treatment decisions right now: the biomarker effect is real and dramatic, but the evidence that it translates into preserved or improved cognitive and neurological function will come from the COMPASS study, not from the Phase 1/2 data. Continued approval may be contingent on those confirmatory trial results.

    The COMPASS Trial: What to Watch

    The Phase 2/3 COMPASS confirmatory trial is the most important ongoing study in this program. It randomizes patients 2:1 to receive either AVLAYAH or idursulfase (the current standard of care, Elaprase), with a planned 96-week treatment duration. The trial is global and includes both pediatric and young adult participants with Hunter syndrome.

    COMPASS is designed to do what the Phase 1/2 study could not: compare AVLAYAH to standard of care in a randomized, controlled design and assess whether the biomarker normalization translates into measurable clinical benefit in terms of cognitive and neurological function. The primary clinical endpoints will need to capture developmental trajectories over time, which is methodologically challenging in a disease with considerable individual variability.

    The trial results are expected to take several years to mature fully. During that time, AVLAYAH is available for clinical use under the accelerated approval, and prescribing decisions will be made on the basis of the current Phase 1/2 biomarker and secondary data.

    What We Still Do Not Know

    Long-term cognitive outcomes

    Biomarker normalization is the most encouraging early signal possible in a disease where the brain has historically been unreachable. Whether it translates into meaningfully preserved or improved cognitive trajectories over years will be answered by COMPASS. That answer will take time and will matter enormously for how this therapy is used and positioned.

    Cost and access

    Denali has not yet publicly announced U.S. list pricing. For ultra-rare disease therapies of this complexity, pricing will directly determine real-world access, especially for families navigating insurance coverage determinations or living outside the United States. The Rare Pediatric Disease Priority Review Voucher granted alongside the approval has significant commercial value for Denali and is a standard incentive mechanism created specifically to encourage development of therapies for conditions like Hunter syndrome, where market size alone does not support development investment. Denali Patient Services is available as a support resource; the practical details of coverage assistance will matter significantly for affected families.

    Global regulatory submissions

    COMPASS is designed to support global regulatory submissions beyond the U.S. Families outside the United States are watching those timelines closely.

    Why This Matters Beyond Hunter Syndrome

    The neuroscience community is watching this approval closely for reasons that extend beyond the MPS II patient population.

    The blood-brain barrier has been one of the central unsolved problems in treating neurological diseases for decades. Most large molecules cannot get through it. Delivering enzyme replacement therapy, gene therapy vectors, antibody-based biologics, or any other large therapeutic molecule to the brain in meaningful concentrations has required either intrathecal delivery (spinal administration) or has simply not been possible at all for most candidates.

    Denali’s TransportVehicle platform is now a clinically validated approach to crossing that barrier in humans, not just a promising hypothesis from animal models. The company has applied the same technology to other conditions, including Alzheimer’s disease-related programs targeting BACE1. This approval is the kind of proof-of-concept that tends to accelerate an entire field of drug development. If COMPASS confirms the clinical benefit and the platform continues to hold up in other applications, the implications extend well beyond lysosomal storage disorders to neurodegenerative disease more broadly.

    For related coverage of other rare pediatric disease FDA approvals and the regulatory frameworks supporting them, see our posts on the first gene therapy for genetic deafness and what the Rare Pediatric Disease PRV means for rare disease development and the UX111 gene therapy BLA for Sanfilippo syndrome now under FDA review.

    For Families and Clinicians

    For patients with Hunter syndrome and their families, AVLAYAH represents the first treatment specifically designed to address the neurological aspect of the disease. The therapy is available in the United States under the accelerated approval. The label specifies initiation in presymptomatic or symptomatic patients prior to advanced neurologic impairment, which underscores the importance of early identification and newborn screening programs for MPS II.

    Optimal management of Hunter syndrome is through a specialist in metabolic or lysosomal storage disorders, ideally at a center with MPS expertise. The National MPS Society provides disease information, family support, a physician directory, and real-time updates on treatment access and the AVLAYAH program. Project Alive focuses specifically on MPS II research and family support. The National Organization for Rare Disorders (NORD) maintains a clinical overview of MPS II with current treatment and research information.

    Sources

    FDA approval press announcement: FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome. FDA.gov. March 25, 2026.

    Denali Therapeutics investor press release: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II). GlobeNewswire. March 25, 2026.

    Phase 1/2 trial primary publication: Phase 1/2 study of tividenofusp alfa in Hunter syndrome. New England Journal of Medicine. January 1, 2026.

    Phase 1/2 trial registration: NCT02055118. ClinicalTrials.gov.

    COMPASS trial search: COMPASS tividenofusp. ClinicalTrials.gov.

    NeurologyLive clinical coverage: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. neurologylive.com. March 2026.

    Child Neurology clinical commentary: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. child-neurology.org. March 2026.

    PharmExec approval coverage: FDA Approves Avlayah for Treatment of Hunter Syndrome. pharmexec.com. 2026.

    Elaprase (idursulfase) FDA approval: FDA approves idursulfase for Hunter syndrome. FDA.gov.

    Blood-brain barrier overview: Blood-Brain Barrier. StatPearls. NCBI.

    TfR1-mediated transcytosis: Transferrin Receptor as a Brain Drug Delivery Vehicle. PMC6558765.

    MPS II/Hunter syndrome GARD: Mucopolysaccharidosis Type II. rarediseases.info.nih.gov.

    IDS gene: IDS gene. NCBI.

    Glycosaminoglycans biology: Glycosaminoglycans. StatPearls. NCBI.

    Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

    Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

    Denali TV platform: Blood-Brain Barrier Science. denalitherapeutics.com.

    Patient resources: National MPS Society | Project Alive | NORD: MPS II | ClinicalTrials.gov: COMPASS

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. AVLAYAH received accelerated approval; continued approval may be contingent on confirmatory trial results from the COMPASS study. Treatment decisions for Hunter syndrome should be made in consultation with a qualified specialist in metabolic or lysosomal storage disorders.